Magrolimab
- CAS No.
- 2169232-81-7
- Chemical Name:
- Magrolimab
- Synonyms
- Magrolimab;Magrolimab (anti-CD47);Research Grade Magrolimab;Hu5F9-G4|||Magrolimab (anti-CD47);Research Grade Magrolimab(DHG17601);Immunoglobulin G4[225-proline], anti-(human CD47 antigen) (human-Mus musculus monoclonal Hu5F9-G4 γ4-chain), disulfide with human-Mus musculus monoclonal Hu5F9-G4 κ-chain, dimer (ACI)
- CBNumber:
- CB78081141
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 90YIEHRFJ9 |
| NCI Drug Dictionary | magrolimab |
Magrolimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | CLA1035 | Magrolimab | 2169232-81-7 | 1mg | $1306.25 | 2026-06-04 | Buy |
| Biosynth | CLA1035 | Magrolimab | 2169232-81-7 | 5mg | $2285.95 | 2026-06-04 | Buy |
| Biosynth | CLA1035 | Magrolimab | 2169232-81-7 | 10mg | $3320.6 | 2026-06-04 | Buy |
| ChemScene | CS-0437418 | Magrolimab 99.92% | 2169232-81-7 | 1mg | $217 | 2026-06-04 | Buy |
| ChemScene | CS-0437418 | Magrolimab 99.92% | 2169232-81-7 | 5mg | $628 | 2026-06-04 | Buy |
Magrolimab Chemical Properties, Uses, Production
Uses
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].
in vivo
Magrolimab (12-100 μg; once daily; 10 days; i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma[1]. Magrolimab (250 μg; once every two days; 7 weeks; i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab[2].
| Animal Model: | Humanized and non-humanized ES xenograft NSG-SGM3 mice[1]. |
| Dosage: | 12-100 μg |
| Administration: | Intraperitoneal injection (i.p.); once daily; 10 days |
| Result: | Inhibited tumor growth and lung metastasis, and prolonged animal survival time. |
| Animal Model: | 4-8 weeks old NSG female breast cancer mouse model[2]. |
| Dosage: | 250 μg |
| Administration: | Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice) |
| Result: | Restricted the Growth of HER2 ADCC-Tolerant Tumors. |
References
[1] Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. DOI:10.3389/fimmu.2023.1277987
[2] Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. DOI:10.1073/pnas.2026849118
[3] Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. DOI:10.1016/j.lfs.2023.121790
Magrolimab Preparation Products And Raw materials
Raw materials
Preparation Products
Magrolimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59929 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
View Latest Price from Magrolimab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Magrolimab
2169232-81-7
|
$163.00-745.00 | 95.00% | 10g | TargetMol Chemicals Inc. |
-
- Magrolimab
2169232-81-7
- $163.00-745.00
- 95.00%
- TargetMol Chemicals Inc.
